ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.

Authors: Aditya Bardia, Virginia G. Kaklamani, Joyce O'Shaughnessy, Peter Schmid, J. Thaddeus Beck, Michelino De Laurentiis, Giuseppe Curigliano, Hope S. Rugo, Carlos Hernando Barcenas, William John Gradishar, Michail Ignatiadis, David A. Cameron, Giulia Tonini, Simona Scartoni, Jennifer A. Crozier, Leonardo Viana Nicacio, Tomer Wasserman, Sara M. Tolaney

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps619

Source: Full article

---

Abstract

TPS619